Cost-Effectiveness of Olaratumab in Combination with Doxorubicin for Patients with Soft Tissue Sarcoma in the United States

Figure 2

Survival estimates. (a) Progression-free survival; (b) overall survival; (c) overall survival validation. For the parametric survival models for PFS and OS, the following covariates were significant in most of the survival models explored and were included in the final set of survival models: tumor type and line of therapy and (where treatment was included as an indicator) the interaction of treatment with tumor type and line of therapy. For OS, the following additional covariates were significant in most models and were also included as covariates in the final analyses: sex and Eastern Cooperative Oncology Group performance status. AIM = ifosfamide + doxorubicin + mesna; Dox = doxorubicin; GemDoc = gemcitabine + docetaxel; MAID = mesna + doxorubicin + ifosfamide + dacarbazine; KM = Kaplan–Meier; Olara + Dox = olaratumab + doxorubicin; PLD = pegylated liposomal doxorubicin.

(a)

(b)

(c)